CA
NZ
UK
AU
IND
US
No press release, regulatory filing orEarningsreport from the company dated November 2 to November 4, 2026 was identified. Without a stated trigger, the likeliest drivers are momentum in low-priced biotech shares, a bounce after recent weakness and speculative positioning ahead of the open. These …
No company announcement dated November 2 to November 4, 2026 was identified, so no catalyst can be confirmed. The most recent news flow includes the October 19, 2026 announcement of a new healthcare customer, and a stock with fewer than 1 million shares outstanding …
Published coverage says new orders improved during the quarter but ended below the company's signed-order targets, which is a leading indicator for next year. GLP-1 customers accounted for about 17% to 18% of third-quarter revenue, and management said lower GLP-1 revenue was offset by …
Curis (NASDAQ:CRIS) was up 83.54%, or USD 0.5964, to USD 1.3103 in pre-market trading on November 4, 2026. No company press release, filing or clinical update dated November 2 to November 4, 2026 was identified, so the jump looks like speculative momentum.
No company press release, regulatory filing or trial readout dated November 3 or November 4, 2026 was identified in the sources reviewed. The company has not confirmed a date for its third-quarter report, so the gain appears to be trading momentum in a low-priced …
The decline fits a longer pattern. The shares closed at USD 1.50 before falling 20.00% to USD 1.20 on May 18, 2026, and the pre-market price is about 85% below that level (calculated). As a penny stock, it carries pronounced volatility, thinLiquidityand dilution risk, …
No company press release or regulatory filing dated November 2 to November 4, 2026 was identified, so no catalyst was found. The company has not announced third quarter results, which market calendars estimate for about November 13, 2026 but which the company has not …
The data were presented on November 1, 2026 at a cardiology conference in San Diego. The company has not tied the share move to the release, and the timing is an inference rather than a confirmed cause.
No company press release,Earningsreport or regulatory filing dated November 2, 3 or 4, 2026 was identified. The move therefore looks like trading driven by a small share base and a thin order book, which is an inference and not a confirmed cause.
● Cash was $586,000 and theWorking CapitalDeficitwas $53.29 million.
Please wait processing your request...